Retatrutide Dosing Explained (Doctor Breaks Down the Data)
A urologist reviews the TRIUMPH-1 retatrutide results, the trial dose ramp, and what he says gray market users do, with repeated warnings about unverified vials.
With Dr. Alex (board-certified urologist, fellowship-trained men's health specialist)
Key moments
Tap a moment to play the video from there.
- 0:00Framing the gray market problemDr. Alex sets up the video around dosing, trial data and what he says the gray market is doing, and teases that the key unknown is the vial rather than the dose.
- 1:46Triple agonist mechanism in briefHe recaps retatrutide as acting on GLP-1, GIP and glucagon receptors and says the glucagon signal adds energy expenditure and liver fat oxidation. He stresses it is not FDA-approved.
- 3:23TRIUMPH-1 phase 3 numbersHe reports average losses of 28.3%, 25.9% and 19% at 12, 9 and 4 mg over 80 weeks, versus 2.2% on placebo, and cautions that cross-trial comparisons are not clean.
- 5:19Heart rate, skin and sleep effectsHe describes dose-dependent GI effects, a resting heart rate increase, skin sensitivity and anecdotal insomnia, rating the evidence for each differently.
- 7:44Disclaimer before the dosing sectionHe says this is not a guide to dosing gray market retatrutide and that he is reporting what happens, not encouraging it.
- 9:10How the trials ramped the doseHe explains the 2 mg start with steps every 4 weeks, and says the slow climb is the main reason people tolerate the drug.
- 10:11The 8 mg liver fat questionHe cites phase two liver fat data that he says plateau between 8 and 12 mg while weight loss continues, then lists caveats showing this is not a proven threshold.
- 11:43What gray market users reportHe says user logs describe starting near 1 mg, adding half to a full mg every 2 to 4 weeks, and settling at 2 to 4 mg a week.
- 13:13Why the vial is the real variableHe argues that unverified purity claims, contamination risk and reconstitution mistakes make actual dose unknowable, and notes the FDA position on compounding.
- 15:16Where he lands on retatrutideHe expects approved use to settle at 4 to 9 mg with 12 mg for some, and says the safest move for most people is to wait for a pharmacy-grade product.
What the video says
Dr. Alex, a urologist who covers peptides and related drugs through the published literature, says retatrutide is still investigational and not FDA-approved. He opens by saying he is not giving a how-to guide. His stated aims are to explain how the trials dosed it, to say what he expects once it reaches the market, and to report what he says people are doing with research-use-only supply.
He summarizes the mechanism as a once-weekly triple agonist acting on GLP-1, GIP and glucagon receptors. He says the glucagon part raises energy expenditure and liver fat burning. He then walks through the TRIUMPH-1 top-line results announced May 21, 2026. In about 2,300 adults with obesity and no diabetes over 80 weeks, he reports average weight loss of 28.3% at 12 mg, 25.9% at 9 mg and 19% at 4 mg, against 2.2% for placebo. He cautions that comparisons with semaglutide and tirzepatide are cross-trial, and that a head-to-head trial against tirzepatide is still to come. On side effects, he describes the usual dose-dependent GI effects, a resting heart rate rise of about six to seven beats per minute at the top dose, skin sensitivity (dysesthesia) in roughly 5 to 13% of trial participants, and insomnia, which he calls anecdotal.
The dosing section covers the trial design: everyone started at 2 mg and stepped up every 4 weeks, so reaching 12 mg took roughly 4 months. Dr. Alex argues that 9 mg looks like the best balance on paper and that more is not automatically better. He also discusses phase two liver fat data, where he says the effect levels off near 8 mg, and he stresses this is a framing and not a proven threshold.
He then reports, without recommending it, that gray market users mostly settle around 2 to 4 mg a week after starting near 1 mg. His central argument is that nobody can verify what is in a research vial, and he lists underdosing, overdosing, contamination and home reconstitution errors as the failure modes. He says the safest course for most people is to wait for an approved product, and he expects real-world dosing to land between 4 and 9 mg.
On each compound
Retatrutide3:23
Dr. Alex reports TRIUMPH-1 average weight loss of 28.3% at 12 mg, 25.9% at 9 mg and 19% at 4 mg over 80 weeks. He also describes heart rate, skin sensitivity and GI effects, and says the unapproved gray market supply has unverified potency.
See how your DNA reads RetatrutideTirzepatide4:50
Dr. Alex ranks retatrutide above tirzepatide on the numbers but says the comparison is cross-trial (80 weeks versus 72). He says a head-to-head trial has not yet reported.
See how your DNA reads TirzepatideSemaglutide4:02
Dr. Alex says Wegovy topped out around 15% weight loss in its trial, below the lowest retatrutide dose in TRIUMPH-1. He also mentions that a higher dose semaglutide has started flagging similar skin sensations.
See how your DNA reads Semaglutide“The drug isn't the variable. It's the supply chain.”
What this video doesn’t settle
- The comparisons with semaglutide and tirzepatide are cross-trial, with different patients and study lengths, and the head-to-head trial against tirzepatide has not reported.
- Long-term cardiac and liver safety data are not yet published, according to Dr. Alex, so the heart rate effect has no long-term verdict.
- The idea that glucagon-driven liver benefit levels off near 8 mg rests on phase two data and is confounded by weight loss, and he calls it a framing rather than a proven threshold.
Questions this video answers
What were the TRIUMPH-1 retatrutide results?
Dr. Alex reports that about 2,300 adults with obesity and no diabetes lost an average of 28.3% of body weight at 12 mg, 25.9% at 9 mg and 19% at 4 mg after 80 weeks. Placebo lost 2.2%. He notes these are top-line figures announced May 21, 2026.
How did the retatrutide trials dose the drug?
According to Dr. Alex, every trial began at 2 mg a week and stepped up every 4 weeks, so reaching 12 mg took roughly 4 months. He says this slow ramp is what makes the drug tolerable.
What side effects of retatrutide does Dr. Alex discuss?
He describes dose-dependent nausea and other GI effects, a resting heart rate rise of about six to seven beats per minute at the top dose, and skin sensitivity in roughly 5 to 13% of trial participants. He calls insomnia anecdotal and not a headline trial finding.
Why does Dr. Alex say gray market retatrutide is risky?
He says research-use-only vials come with unverified certificates and purity claims, so the actual dose is unknown. He lists underdosed or overdosed vials, contamination and home reconstitution errors as the main failure modes.
What dose does Dr. Alex expect once retatrutide is approved?
He expects real-world dosing to settle in a 4 to 9 mg band, with 12 mg reserved for people who need maximum loss and can tolerate it. He gives average losses of roughly 20 to 28% as his forward reading of the data.
Video by Dr. Alex Tatem on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
